Revenue of LEQEMBI (Preliminary Basis)
Filed with TSE · · 1 page · English
Summary by 6ix AI
The revenue reached a significant amount, showing an increase compared to the same period last year, despite stockpiling impacts in China. Revenue breakdown indicates substantial contributions from major markets, including the United States, Japan, and China. This announcement coincides with Biogen Inc.'s upcoming financial results disclosure, with Eisai's detailed financial results set for a later date.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Eisai's latest callEisai (Tokyo:4523) Q1 2027 Earnings Call · Replay · Aug 3Read the transcript of Eisai (Tokyo:4523) Q1 2027 Earnings CallEarlier from Eisai
- Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
Later from Eisai
- Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
- CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2026
- LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
- Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Follow Eisai into a list and get an email when it puts out news.
Follow Eisai